

Edgar Filing: SOMANETICS CORP - Form 10-Q

SOMANETICS CORP  
Form 10-Q  
October 12, 2005

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

FORM 10-Q

(Mark One)

Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

For the quarterly period ended AUGUST 31, 2005

OR

Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

For the transition period from \_\_\_\_\_ to \_\_\_\_\_

Commission file number 0-19095

SOMANETICS CORPORATION  
(Exact name of registrant as specified in its charter)

MICHIGAN  
(State or other jurisdiction of  
incorporation or organization)

38-2394784  
(I.R.S. Employer Identification No.)

1653 EAST MAPLE ROAD,  
TROY, MICHIGAN  
48083-4208  
(Address of principal executive offices)  
(Zip Code)

(248) 689-3050  
(Registrant's telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes    X    No  
-----

Indicate by check mark whether the registrant is an accelerated filer (as defined in Rule 12b-2 of the Exchange Act).

Yes                    No    X  
-----

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Edgar Filing: SOMANETICS CORP - Form 10-Q

Yes            No    X  
 -----      -----

Number of common shares outstanding at October 12, 2005: 10,683,179

PART I FINANCIAL INFORMATION

SOMANETICS CORPORATION

BALANCE SHEETS

	August 31, 2005	November 2004
	----- (Unaudited)	----- (Audited)
<b>ASSETS</b>		
<b>CURRENT ASSETS:</b>		
Cash and cash equivalents .....	\$ 11,699,124	\$ 7,069
Accounts receivable .....	2,464,357	2,022
Inventory .....	920,037	682
Prepaid expenses .....	153,982	257
Deferred tax asset - current .....	743,429	510
	-----	-----
Total current assets .....	15,980,929	10,542
	-----	-----
<b>PROPERTY AND EQUIPMENT (at cost):</b>		
Demonstration and no-cap sales equipment at customers .....	1,859,228	1,628
Machinery and equipment .....	754,506	704
Furniture and fixtures .....	289,397	255
Leasehold improvements .....	187,136	171
	-----	-----
Total .....	3,090,267	2,759
Less accumulated depreciation and amortization .....	(1,768,300)	(1,675)
	-----	-----
Net property and equipment .....	1,321,967	1,084
	-----	-----
<b>OTHER ASSETS:</b>		
Deferred tax asset - non-current .....	4,695,348	6,190
Intangible assets, net .....	947,742	952
Other .....	15,000	15
	-----	-----
Total other assets .....	5,658,090	7,157
	-----	-----
<b>TOTAL ASSETS .....</b>	<b>\$ 22,960,986</b>	<b>\$ 18,784</b>
	=====	=====
<b>LIABILITIES AND SHAREHOLDERS' EQUITY</b>		
<b>CURRENT LIABILITIES:</b>		
Accounts payable .....	\$ 646,550	\$ 529
Accrued liabilities .....	881,531	703
	-----	-----
Total current liabilities .....	1,528,081	1,232
	-----	-----
<b>COMMITMENTS AND CONTINGENCIES</b>		
<b>SHAREHOLDERS' EQUITY:</b>		
Preferred shares; authorized, 1,000,000 shares of \$.01 par value; no shares issued or outstanding .....		--
Common shares; authorized, 20,000,000 shares of \$.01 par value;		

## Edgar Filing: SOMANETICS CORP - Form 10-Q

issued and outstanding, 10,427,133 shares at August 31, 2005,		
and 10,137,782 shares at November 30, 2004 .....	104,271	101
Additional paid-in capital .....	63,762,525	62,333
Accumulated deficit .....	(42,433,891)	(44,882)
<hr/>		
Total shareholders' equity .....	21,432,905	17,552
<hr/>		
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY .....	\$ 22,960,986	\$ 18,784
<hr/>		

See notes to financial statements

2

### SOMANETICS CORPORATION

#### STATEMENTS OF OPERATIONS (Unaudited)

	Three Months Ended August 31,		Nine Months Ended August 31,	
	2005	2004	2005	2004
NET REVENUES .....	\$ 5,242,848	\$ 3,076,373	\$14,358,211	\$ 8,779,6
COST OF SALES .....	661,196	443,837	1,856,185	1,483,5
GROSS MARGIN .....	4,581,652	2,632,536	12,502,026	7,296,0
<hr/>				
OPERATING EXPENSES:				
Research, development and engineering ..	95,924	87,001	296,441	269,4
Selling, general and administrative ....	3,064,857	2,019,128	8,685,648	5,810,6
Total operating expenses .....	3,160,781	2,106,129	8,982,089	6,080,0
OPERATING INCOME .....	1,420,871	526,407	3,519,937	1,215,9
<hr/>				
OTHER INCOME:				
Interest income .....	85,413	13,315	189,542	26,2
Total other income .....	85,413	13,315	189,542	26,2
NET INCOME BEFORE INCOME TAXES .....	1,506,284	539,722	3,709,479	1,242,1
<hr/>				
INCOME TAX PROVISION .....	512,136	--	1,261,223	
NET INCOME .....	\$ 994,147	\$ 539,722	\$ 2,448,256	\$ 1,242,1
<hr/>				
NET INCOME PER COMMON SHARE - BASIC .....	\$ 0.10	\$ 0.05	\$ 0.24	\$ 0.

NET INCOME PER COMMON

Edgar Filing: SOMANETICS CORP - Form 10-Q

SHARE - DILUTED .....	\$ 0.08	\$ 0.05	\$ 0.21	\$ 0.
WEIGHTED AVERAGE SHARES OUTSTANDING - BASIC .....	10,360,990	10,098,237	10,227,923	9,662,7
WEIGHTED AVERAGE SHARES OUTSTANDING - DILUTED .....	12,102,611	11,913,495	11,850,418	11,353,9

See notes to financial statements

3

SOMANETICS CORPORATION  
STATEMENTS OF CASH FLOWS  
(UNAUDITED)

	For the Nine Month Periods Ended	
	August 31, 2005	August 31, 2004
CASH FLOWS FROM OPERATING ACTIVITIES:		
Net income .....	\$ 2,448,256	\$1,242,197
Adjustments to reconcile net income to net cash provided by operations:		
Income tax provision .....	1,261,223	--
Depreciation and amortization .....	276,967	199,317
Compensation expense for non-employee stock options .....	7,013	--
Changes in assets and liabilities:		
Accounts receivable (increase) decrease .....	(441,813)	268,256
Inventory (increase) .....	(627,277)	(91,332)
Prepaid expenses decrease .....	103,911	17,620
Accounts payable increase (decrease) .....	117,453	(125,746)
Accrued liabilities increase .....	178,422	18,981
Net cash provided by operations .....	3,324,155	1,529,293
CASH FLOWS FROM INVESTING ACTIVITIES:		
Acquisition of property and equipment (net) .....	(119,543)	(93,169)
Net cash (used in) investing activities .....	(119,543)	(93,169)
CASH FLOWS FROM FINANCING ACTIVITIES:		
Proceeds from issuance of common shares due to exercise of stock options and warrants .....	1,424,970	2,666,022
Net cash provided by financing activities .....	1,424,970	2,666,022
NET INCREASE IN CASH AND CASH EQUIVALENTS .....	4,629,582	4,102,146
CASH AND CASH EQUIVALENTS, BEGINNING		

Edgar Filing: SOMANETICS CORP - Form 10-Q

OF PERIOD .....	7,069,542	2,239,192
	-----	-----
CASH AND CASH EQUIVALENTS, END		
OF PERIOD .....	\$11,699,124	\$6,341,338
	=====	=====
Supplemental Disclosure of Non cash investing activities:		
Demonstration and no-cap sales equipment capitalized		
from inventory (Note 2) .....	\$ 390,150	\$ 404,777

See notes to financial statements

4

SOMANETICS CORPORATION

NOTES TO FINANCIAL STATEMENTS  
(UNAUDITED)

AUGUST 31, 2005

1. FINANCIAL STATEMENT PRESENTATION

We prepared our unaudited interim financial statements pursuant to the Securities and Exchange Commission's rules. These interim financial statements do not include all of the information and notes normally included in our annual financial statements prepared in accordance with generally accepted accounting principles. We believe, however, that the disclosures are adequate to make the information presented not misleading.

The unaudited interim financial statements in this report reflect all adjustments which are, in our opinion, necessary to a fair statement of the results for the interim periods presented. All of these adjustments that are material are of a normal recurring nature. Our operating results for the nine-month period ended August 31, 2005 do not necessarily indicate the results that you should expect for the year ending November 30, 2005. You should read the unaudited interim financial statements together with the financial statements and related notes for the year ended November 30, 2004 included in our Annual Report on Form 10-K for the fiscal year ended November 30, 2004.

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Inventory is stated at the lower of cost or market on a first-in, first-out (FIFO) basis. Inventory consists of:

	August 31, 2005	November 30, 2004
	-----	-----
Finished goods .....	\$449,651	\$358,815
Purchased components ..	430,401	323,053
Work in process .....	39,985	1,042
	-----	-----
Total .....	\$920,037	\$682,910
	=====	=====

Property and Equipment are stated at cost. Depreciation and amortization are computed using the straight-line method over the estimated useful lives of the assets, which range from two to five years. We offer to our United States

## Edgar Filing: SOMANETICS CORP - Form 10-Q

customers a no-cap sales program whereby we ship the Cerebral Oximeter to the customer at no charge, in exchange for the customer agreeing to purchase SomaSensors. The Cerebral Oximeters that are shipped to our customers are classified as no-cap sales equipment and are depreciated over five years. During the first nine months of fiscal 2005 and fiscal 2004, costs capitalized from inventory for Cerebral Oximeters being used as demonstration and no-cap sales equipment at customer locations were approximately \$390,000 and \$405,000, respectively. Property and equipment are reviewed for impairment whenever events or changes in circumstances indicate that the net book value of the asset may not be recovered.

Intangible Assets consist of patents and trademarks, and license acquisition costs. Patents and trademarks are recorded at cost and are being amortized on the straight-line method over 17 years. The carrying amount and accumulated amortization of these patents and trademarks are as follows:

	August 31, 2005	November 30, 2004
	-----	-----
Patents and trademarks .....	\$111,733	\$111,733
Less accumulated amortization .....	(93,084)	(87,900)
	-----	-----
Total .....	\$ 18,649	\$ 23,833
	=====	=====

5

### SOMANETICS CORPORATION

#### NOTES TO FINANCIAL STATEMENTS (UNAUDITED)

AUGUST 31, 2005

Amortization expense for the nine months ended August 31, 2005 and August 31, 2004 was approximately \$5,200. Amortization expense for each of the next three fiscal years is expected to be approximately \$6,900 per year, and approximately \$3,100 in fiscal 2008.

License acquisition costs are related to our acquisition of exclusive, worldwide, royalty-bearing licenses to specified rights relating to the CorRestore System, and related products and accessories. In exchange for the licenses and consulting services, we agreed to the following compensation for CorRestore LLC and its agent, Joe B. Wolfe: (1) a royalty of 10% of our "net sales" of products subject to the licenses, (2) five-year warrants to purchase up to 400,000 common shares at \$3.00 a share, exercisable to purchase 300,000 shares immediately and to purchase an additional 50,000 shares upon our receipt of clearance or approval from the FDA to market the CorRestore Patch in the United States and another 50,000 shares upon our receipt of CE certification for the CorRestore System, (3) additional five-year warrants to purchase up to 2,100,000 common shares at \$3.00 a share, granted when we received clearance from the FDA to market the CorRestore Patch in the United States, exercisable based on our cumulative net sales of the CorRestore System products, and (4) a consulting fee of \$25,000 a year to each of the inventors until we sell 1,000 CorRestore Patches.

In April 2004, CorRestore LLC exercised its warrant to purchase 380,000 of our newly-issued common shares, at \$3.00 per share, for proceeds of \$1,140,000.

Edgar Filing: SOMANETICS CORP - Form 10-Q

In May 2005, Joe B. Wolfe, agent for CorRestore LLC and one of our former directors, purchased 20,000 common shares under his warrants by a cashless exercise. As a result of this cashless exercise, we issued 16,264 common shares to Mr. Wolfe, retaining 3,736 common shares in payment of the exercise price. CorRestore LLC and Mr. Wolfe have no vested warrants remaining to purchase common shares.

License acquisition costs consist of professional service fees recorded at cost, our estimate of the fair value of the ten-year vested stock options to purchase 50,000 common shares at \$3.00 a share granted to one of our then current directors in connection with negotiating and assisting us in completing the transaction, and our estimate of the fair value of the 400,000 common share vested portion of the five-year warrants to purchase common shares at \$3.00 a share issued in the transaction. Consistent with the treatment of the warrants to purchase 400,000 common shares, we intend to include in license acquisition costs, and additional paid in capital, the fair value of the vested portion of the warrants to purchase 2,100,000 common shares, estimated using the Black-Scholes valuation model, when and if they become vested. However, we do not expect any of these warrants to become vested before their November 21, 2006 expiration date, based on sales of CorRestore products to date.

The total carrying amount of these license acquisition costs is as follows:

	August 31, 2005 -----	November 30, 2004 -----
License acquisition costs ..	\$929,093	\$929,093

License acquisition costs are intangible assets with indefinite lives that are reviewed annually for impairment at the end of our fiscal year, and whenever events or changes in circumstances indicate that the carrying value of the asset may not be recovered. We evaluate impairment by comparing the fair value of the intangible asset, determined using a cash flow method, with its carrying value.

SOMANETICS CORPORATION

NOTES TO FINANCIAL STATEMENTS  
(UNAUDITED)

AUGUST 31, 2005

Stock Options In October 1995, Statement of Financial Accounting Standards No. 123, "Accounting for Stock-Based Compensation," was issued. In December 2004, the Financial Accounting Standards Board issued Statement of Financial Accounting Standards No. 123 (revised), Share Based Payment. This Statement revises Statement No. 123, "Accounting for Stock-Based Compensation," and requires that compensation costs related to share-based payment transactions, including stock options, restricted stock and restricted stock units be recognized in the financial statements. This Statement will be effective for our fiscal quarter ending February 28, 2006. We expect the equity compensation to be recognized in our statement of operations for fiscal 2006, related to unvested stock options as of our required adoption date, will be the equivalent of \$.03 per diluted common share. Future equity compensation grants in 2005 and beyond would have an additional impact on our financial statements.

We currently account for stock-based compensation of employees using the

## Edgar Filing: SOMANETICS CORP - Form 10-Q

intrinsic value method prescribed in Accounting Principles Board Opinion No. 25, "Accounting for Stock Issued to Employees," and related interpretations. However, we have also adopted the enhanced disclosure provisions as defined by Statement No. 148, "Accounting for Stock-Based Compensation - Transition and Disclosure." Stock-based compensation of consultants and advisors is determined based on the fair value of the options or warrants on the grant date pursuant to the methodology of SFAS No. 123, estimated using the Black-Scholes model. The resulting amount is recognized as compensation expense and an increase in additional paid-in capital over the vesting period of the options or warrants. As a result, we recorded \$7,013 of compensation expense, and an equal increase in additional paid in capital, for stock options issued to non-employees during the first three quarters of fiscal 2005, and we recorded no such expense in fiscal 2004. During the first three quarters of fiscal 2005 we granted 168,257 stock options to our employees, directors and one of our consultants, and we issued 273,087 newly-issued common shares as a result of stock option exercises. During the first three quarters of fiscal 2004, we granted 50,500 stock options to our employees and directors, and we issued 318,276 newly-issued common shares as a result of stock option exercises.

Had compensation expense for stock options that vested in the first three quarters been determined based on the fair value of the options on the grant date pursuant to the methodology of SFAS No. 123, our results of operations, on a pro forma basis, would have been as follows:

	FOR THE THREE MONTHS ENDED		FOR THE NINE
	AUGUST 31, 2005	AUGUST 31, 2004	AUGUST 31, 2005
Net income .....	\$ 994,147	\$ 539,722	\$ 2,448,256
Add: Stock-based employee compensation included in actual net income .....	\$ 4,208	\$ 0	\$ 7,013
Deduct: Total stock-based employee compensation expense, had fair value method been applied .....	\$ (721,957)	\$ (197,198)	\$ (1,315,687)
Pro-forma net income .....	\$ 276,398	\$ 342,524	\$ 1,139,582
Net income per common share - diluted .....	\$ .08	\$ .05	\$ .21
Pro forma net income per common share - diluted .....	\$ .02	\$ .03	\$ .10

7

SOMANETICS CORPORATION

NOTES TO FINANCIAL STATEMENTS  
(UNAUDITED)

AUGUST 31, 2005

Net Income Per Common Share - basic and diluted is computed using the weighted average number of common shares outstanding during each period. Weighted average shares outstanding - diluted includes the potential dilution that could occur for common stock issuable under stock options or warrants. The difference between weighted average shares - diluted and weighted average shares - basic is calculated as follows:



Edgar Filing: SOMANETICS CORP - Form 10-Q

	2005	
	Three Months	Nine Months
Weighted average shares - basic	10,360,990	10,227,923
Add: effect of dilutive common shares and warrant	1,741,621	1,622,495
Weighted average shares - diluted	12,102,611	11,850,418

	2004	
	Three Months	Nine Months
Weighted average shares - basic	10,098,237	9,662,716
Add: effect of dilutive common shares and warrant	1,815,258	1,691,239
Weighted average shares - diluted	11,913,495	11,353,955

For the three and nine months ended August 31, 2005, the number of stock options that were excluded from the computation of net income per common share - diluted, because the exercise price of the options exceeded the average price per share of our common shares, was approximately 500, and the number of warrants excluded from the calculation was 2,100,000, as they are contingent on achieving specified future sales targets that we do not expect to achieve. For the three and nine months ended August 31, 2004, there were approximately 22,000 stock options outstanding that were excluded from the computation of net income per common share - diluted, and there were approximately 1,866,000 warrants outstanding that were excluded from the computation. As of August 31, 2005 and August 31, 2004, we had outstanding warrants and options to purchase common shares of 4,303,151 and 4,439,915, respectively.

Reclassifications Certain reclassifications have been made to the financial statements for 2004 to conform to 2005 presentation.

### 3. INCOME TAXES

During fiscal 2004, we adjusted our deferred tax asset valuation allowance resulting in the recognition of a deferred tax asset of \$6,700,000 related to the expected future benefits of our net operating loss carryforwards, in accordance with Statement of Financial Accounting Standards No. 109, "Accounting for Income Taxes." We have performed the required assessment of positive and negative evidence regarding realization of our deferred tax assets in accordance with SFAS No. 109, including our past operating results, the existence of cumulative losses over our history up to the most recent two fiscal years, and our forecast for future net income. The primary assumption underlying our determination that the net asset will be realized is that our revenues and pre-tax income will grow in future years consistent with the original growth guidance given for fiscal 2005. Our assessment of our deferred tax assets, and the reversal of part of our valuation allowance, included evaluating our financial plans and our future projected earnings, making allowance for the uncertainties surrounding, among other things, our future rate of growth in net

## Edgar Filing: SOMANETICS CORP - Form 10-Q

revenues, the rate of adoption of our products in the marketplace, and the potential for competition to enter the marketplace.

8

### SOMANETICS CORPORATION

#### NOTES TO FINANCIAL STATEMENTS (UNAUDITED)

AUGUST 31, 2005

In reversing a portion of our valuation allowance, we have concluded that it is more likely than not that such assets will be realized. Given the assumptions inherent in our financial plans, it is possible to calculate a different value for our deferred tax asset by changing one or more of the variables in our assessment. However, we believe that our evaluation of our financial plans was reasonable, and that the judgments and assumptions that we made at the time of developing the plan were appropriate.

During the first quarter of fiscal 2005, we began recognizing income tax expense at an estimated effective tax rate of 34% on our statement of operations. As we assess our plans for future years, we will continue to review the appropriateness of adjusting our deferred tax asset valuation allowance and recognizing additional net deferred tax assets.

#### 4. ACCRUED LIABILITIES

Accrued liabilities consist of the following:

	August 31, 2005	November 30, 2004
	-----	-----
Incentive compensation ..	\$471,548	\$390,978
Sales commissions .....	256,352	153,180
Professional fees .....	115,225	42,000
Warranty .....	14,800	10,750
401(k) match .....	13,160	97,071
Royalty .....	10,445	9,130
	-----	-----
Total .....	\$881,530	\$703,109
	=====	=====

#### 5. COMMITMENTS AND CONTINGENCIES

We may become subject to products liability claims by patients or physicians, and may become a defendant in products liability or malpractice litigation. We have obtained products liability insurance and an umbrella policy. We might not be able to maintain such insurance or such insurance might not be sufficient to protect us against products liability.

We have employment agreements or change in control, invention, confidentiality, non-compete and non-solicitation agreements with all of our executive officers. The employment agreement with our Vice President, Sales and Marketing and the change in control agreements with five of our executive officers provide for severance benefits equal to one year's salary upon termination of employment without cause or for good reason 90 days before to one year after a change in control of the Company that occurs by June 13, 2008. The

## Edgar Filing: SOMANETICS CORP - Form 10-Q

employment agreement with our President and Chief Executive Officer provides for severance benefits equal to one year's salary and six months of benefits upon termination of his employment without cause or if his employment terminates because his agreement expires. His employment agreement expires April 30, 2006 unless earlier terminated as provided in the agreement. All executive officers have agreed not to compete with us and not to solicit our employees during specified periods following the termination of employment, and they have agreed to various confidentiality obligations. The estimated financial exposure of these employment agreements, upon a change of control of the Company and termination of all of the executives without cause, is approximately \$934,000.

9

### SOMANETICS CORPORATION

#### NOTES TO FINANCIAL STATEMENTS (UNAUDITED)

AUGUST 31, 2005

#### 6. COMMON STOCK

On April 21, 2005, our shareholders approved the Somanetics Corporation 2005 Stock Incentive Plan. The Plan permits us to grant stock options, including both nonqualified options and incentive options, restricted stock and restricted stock units to our officers, other employees, non-employee directors, consultants, advisors, independent contractors and agents, up to 600,000 common shares.

In April 2005, we granted 10-year options under the 1997 Stock Option Plan to purchase 67,041 common shares, and 10-year options under the 2005 Stock Incentive Plan to purchase 71,216 common shares, to 20 of our employees and one of our consultants at an exercise price of \$13.55 per share (the average of the high and low sale prices of the common shares as of the date of grant). In May 2005, we granted 10-year options under the 2005 Stock Incentive Plan to purchase 30,000 common shares to three of our directors at an exercise price of \$14.92 per share (the average of the high and low sale prices of the common shares as of the date of grant).

During the first three quarters of fiscal 2005, we issued 273,087 common shares as a result of stock option exercises for proceeds of approximately \$1,425,000.

In May 2005, Joe B. Wolfe, agent for CorRestore LLC and one of our former directors, purchased 20,000 common shares under his warrants by a cashless exercise. As a result of this cashless exercise, we issued 16,264 common shares to Mr. Wolfe, retaining 3,736 common shares in payment of the exercise price. Mr. Wolfe has no vested warrants remaining to purchase common shares.

#### 7. SEGMENT INFORMATION

We operate our business in one reportable segment, the development, manufacture and marketing of medical devices. Each of our two product lines have similar characteristics, customers, distribution and marketing strategies, and are subject to similar regulatory requirements. In addition, in making operating and strategic decisions, our management evaluates net revenues based on the worldwide net revenues of each major product line, and profitability on an enterprise-wide basis due to shared costs. Approximately 97% of our net revenues in the first three quarters of fiscal 2005 were derived from our INVOS Cerebral Oximeter product line, compared to 95% of our net revenues in the first three quarters of fiscal 2004.

SOMANETICS CORPORATION

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL  
CONDITION AND RESULTS OF OPERATIONS

AUGUST 31, 2005

Some of the statements in this report are forward-looking statements. These forward-looking statements include statements relating to our performance in this Management's Discussion and Analysis of Financial Condition and Results of Operations. In addition, we may make forward-looking statements in future filings with the Securities and Exchange Commission and in written material, press releases and oral statements issued by us or on our behalf. Forward-looking statements include statements regarding the intent, belief or current expectations of us or our officers, including statements preceded by, followed by or including forward-looking terminology such as "may," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict" or similar expressions, with respect to various matters.

Our actual results might differ materially from those projected in the forward-looking statements depending on various important factors. These important factors include economic conditions in general and in the healthcare market, the demand for and market for our products in domestic and international markets, our current dependence on the Cerebral Oximeter and SomaSensor, the challenges associated with developing new products and obtaining regulatory approvals if necessary, research and development activities, the uncertainty of acceptance of our products by the medical community, the lengthy sales cycle for our products, third party reimbursement, competition in our markets, including the potential introduction of competitive products by others, our dependence on our distributors, physician training, enforceability and the costs of enforcement of our patents, potential infringements of our patents and the other factors discussed under the caption "Risk Factors" and elsewhere in our Registration Statement on Form S-1 (file no. 333-74788) effective January 11, 2002 and elsewhere in this report, all of which constitute cautionary statements identifying important factors with respect to the forward-looking statements, including certain risks and uncertainties, that could cause actual results to differ materially from those in such forward-looking statements.

All forward-looking statements in this report are based on information available to us on the date of this report. We do not undertake to update any forward-looking statements that may be made by us or on our behalf in this report or otherwise.

RESULTS OF OPERATIONS

OVERVIEW

We develop, manufacture and market the INVOS Cerebral Oximeter, the only non-invasive patient monitoring system commercially available in the United States that continuously measures changes in the blood oxygen level in the brain. We also develop and market the CorRestore System for use in cardiac repair and reconstruction, including heart surgeries called surgical ventricular restoration, or SVR.

During fiscal 2004 and the first three quarters of fiscal 2005, our primary activities consisted of sales and marketing of the Cerebral Oximeter, the related disposable SomaSensor, and the CorRestore System.

## Edgar Filing: SOMANETICS CORP - Form 10-Q

We derive our revenues from sales of Cerebral Oximeters, SomaSensors and CorRestore Systems to our distributors and to hospitals in the United States through our direct sales employees and independent sales representative firms. We offer to our customers in the United States a no-cap sales program whereby we ship the Cerebral Oximeter to the customer at no charge, in exchange for the customer agreeing to purchase SomaSensors. Payment terms are generally net 30 days for United States sales and net 60 days or longer for international sales. Our primary expenses, excluding the cost of our products, are selling, general and administrative and research, development and engineering.

11

### SOMANETICS CORPORATION

#### MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

AUGUST 31, 2005

As described in more detail below, for the nine months ended August 31, 2005, we achieved an increase in net income before income taxes of approximately 199%, primarily as a result of an increase in net revenues of approximately 64% and an increase in gross margin percentage to approximately 87%. Our increase in net revenues was primarily a result of increased unit sales and increased average selling prices for our disposable SomaSensor in the United States, increased sales of the Cerebral Oximeter to pediatric hospitals in the United States and increased international sales. Our increase in gross margin percentage was also primarily attributable to the increased sales of the Cerebral Oximeter to pediatric hospitals and the increase in the average selling prices for our disposable SomaSensors, as well as the reduction in the cost of our disposable SomaSensor by approximately 40%, effective May 2004, as a result of changes in our manufacturing process. Our operating expenses increased approximately 48% for the nine month period primarily due to our hiring additional sales personnel in fiscal 2004 and 2005, increased commissions paid to our independent sales representative firms and direct sales employees as a result of increased sales, increased selling expenses, increased accrued incentive compensation and costs associated with our first Sarbanes-Oxley internal control assessment. We had approximately \$3,324,000 of cash provided by operations in the first three quarters of fiscal 2005, and a net increase in cash and cash equivalents of approximately \$4,630,000.

For 2005, we project an increase in net revenues of approximately 59% to 63%, to approximately \$20.0 million to \$20.5 million, and we also project an increase in net income before income taxes of approximately 135% to 150%, to approximately \$4.7 million to \$5.0 million. In addition, we expect to realize a net increase in cash and cash equivalents of approximately \$5.4 million, and we expect that our year-end cash balances will be approximately \$12.5 million. While we do not expect to pay income taxes for fiscal 2005, beginning in the first quarter of 2005, we began recognizing income tax expense at an estimated effective tax rate of 34% on our statement of operations. As we assess our plans for future years, we will continue to review the appropriateness of adjusting our deferred tax asset valuation allowance and recognizing additional net deferred tax assets.

THREE MONTHS ENDED AUGUST 31, 2005 COMPARED TO THREE MONTHS ENDED AUGUST 31, 2004

Our net revenues increased \$2,166,475, or 70%, from \$3,076,373 in the three-month period ended August 31, 2004 to \$5,242,848 in the three-month period ended August 31, 2005. The increase in net revenues is attributable to

Edgar Filing: SOMANETICS CORP - Form 10-Q

- an increase in United States sales of approximately \$1,814,000, or 70%, from approximately \$2,600,000 in the third quarter of fiscal 2004 to approximately \$4,414,000 in the third quarter of fiscal 2005. This increase is primarily due to an increase in sales of the disposable SomaSensor of approximately \$1,492,000, or 64%, as a result of a 45% increase in SomaSensor unit sales, driven primarily by increased sales personnel and recent clinical research data, and a 13% increase in SomaSensor average selling prices. In addition, Cerebral Oximeter revenues increased approximately \$346,000, or 241%, due to increased purchases by pediatric hospitals, and
- an increase in international sales of approximately \$353,000, or 74%, from approximately \$476,000 in the third quarter of fiscal 2004 to approximately \$829,000 in the third quarter of fiscal 2005, primarily attributable to increased purchases of the Cerebral Oximeter by Tyco Healthcare.

12

SOMANETICS CORPORATION

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL  
CONDITION AND RESULTS OF OPERATIONS

AUGUST 31, 2005

As described above, during the third quarter we achieved a 13% increase in the average selling price of SomaSensors in the United States. The increase in the average selling price is primarily attributable to the addition of new customers at our higher suggested retail prices and increased sales of our pediatric SomaSensor, which sells for a premium price. In addition, as described above, we had a 45% increase in SomaSensor unit sales in the United States to 41,720 units. We expect that the average selling price of SomaSensors in the United States will increase by at least 10% in 2005 compared to 2004 as a result of the factors described above.

We placed 76 new Cerebral Oximeters in the United States in the third quarter of 2005, and we estimate that the installed base of Cerebral Oximeters in the United States is approximately 985, in approximately 455 hospital accounts, as of August 31, 2005. Internationally we sold 58 Cerebral Oximeters and 13,290 SomaSensors during the third quarter of 2005.

Approximately 16% of our net revenues in the third quarter of fiscal 2005 were from export sales, compared to approximately 15% in the third quarter of fiscal 2004. We expect international net revenues to represent approximately 15% to 20% of total net revenues in 2005. During the third quarter of 2005, one international distributor (Europe) represented approximately 12% of our net revenues, and during the third quarter of fiscal 2004, one international distributor (Europe) represented approximately 10% of our net revenues.

Sales of our products as a percentage of net revenues were as follows:

	PERCENT OF NET REVENUE	
	THIRD QUARTER OF FISCAL	
	-----	
PRODUCT	2005	2004
-----	----	----

## Edgar Filing: SOMANETICS CORP - Form 10-Q

SomaSensors.....	79%	85%
Cerebral Oximeters...	19%	11%
CorRestore Systems...	2%	4%
	---	---
Total.....	100%	100%
	===	===

For 2005, we expect sales of SomaSensors to account for 75% to 80% of net revenues, sales of Cerebral Oximeters 20% to 25%, and sales of CorRestore Systems less than 5%.

Gross margin as a percentage of net revenues was approximately 87% for the quarter ended August 31, 2005 and approximately 86% for the quarter ended August 31, 2004. The increase in gross margin as a percentage of net revenues is primarily attributable to the increase in the average selling price of SomaSensors described above, and increased sales of the Cerebral Oximeter to pediatric hospitals in the United States. We expect our gross margin percentage to be approximately 87% in fiscal 2005, primarily due to the factors described above.

Our research, development and engineering expenses increased \$8,923, or 10%, from \$87,001 for the three months ended August 31, 2004 to \$95,924 for the three months ended August 31, 2005. The increase is primarily attributable to increased development costs associated with the Cerebral Oximeter. We expect our research and development expenses to increase in the fourth quarter of 2005 primarily as a result of design and development costs associated with our next generation cerebral oximeter and smaller pediatric SomaSensor, and the addition of one engineer.

13

### SOMANETICS CORPORATION

#### MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

AUGUST 31, 2005

Selling, general and administrative expenses increased approximately \$1,046,000, or 52%, from \$2,019,128 for the quarter ended August 31, 2004 to \$3,064,857 for the quarter ended August 31, 2005, primarily due to a 53% increase in our sales and marketing expenses during the third quarter of fiscal 2005 because of our increased sales personnel and our increased sales and marketing efforts. The increase in selling, general and administrative expense is primarily attributable to

- a \$251,000 increase in salaries, wages, and related expenses, primarily as a result of an increase in the number of employees, principally sales and marketing (from an average of 34 employees for the third quarter ended August 31, 2004 to an average of 43 employees for the third quarter ended August 31, 2005),
- a \$199,000 increase in commissions paid to our independent sales representative firms as a result of increased sales,
- a \$186,000 increase in commissions paid to our sales employees, as a result of hiring additional sales employees in fiscal 2004 and 2005 and increased sales,
- a \$185,000 increase in audit-related expenses, primarily as a

## Edgar Filing: SOMANETICS CORP - Form 10-Q

result of costs associated with our first internal control assessment under Section 404 of the Sarbanes-Oxley Act and related regulations,

- a \$109,000 increase in accrued incentive compensation expense due to our year-to-date 2005 financial performance, primarily increased sales and net income, in accordance with the 2005 Incentive Compensation Plan,
- a \$103,000 increase in travel, training, trade show and selling-related expenses as a result of our increased sales personnel and increased sales and marketing efforts, and
- \$42,000 in costs for the third quarter of fiscal 2005 associated with our employer 401(k) matching program, which was implemented in the fourth quarter of fiscal 2004.

We expect our selling, general and administrative expenses to increase further in fiscal 2005, primarily as a result of our current plans to hire additional direct sales personnel in fiscal 2005, increased sales commissions payable to our direct sales personnel and independent sales representative firms as sales increase, and increased sales and marketing expenses.

During the third quarter of fiscal 2005, we recognized income tax expense at an estimated effective tax rate of 34% in our statement of operations, and we expect this to continue for future periods.

For the three-month period ended August 31, 2005, we realized net income of \$.08 per diluted common share, compared to \$.05 per diluted common share for the third quarter of 2004. The increase in net income per diluted common share is primarily attributable to

- a 70% increase in net revenues,
- an increase in gross margin percentage to 87% from 86%, and
- a \$72,000 increase in interest income.

We achieved the increase in net income despite a 50% increase in operating expenses and the recognition of income tax expense.

14

SOMANETICS CORPORATION

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL  
CONDITION AND RESULTS OF OPERATIONS

AUGUST 31, 2005

NINE MONTHS ENDED AUGUST 31, 2005 COMPARED TO NINE MONTHS ENDED AUGUST 31, 2004

Our net revenues increased \$5,578,597, or 64%, from \$8,779,614 in the nine-month period ended August 31, 2004 to \$14,358,211 in the nine-month period ended August 31, 2005. The increase in net revenues is attributable to

- an increase in United States sales of approximately \$4,586,000, or 62%, from approximately \$7,390,000 in the first three quarters of fiscal 2004 to approximately \$11,976,000 in the first three quarters of fiscal 2005. This increase is primarily due to an increase in sales of the disposable SomaSensor of approximately \$3,702,000, or 58%, as a



## Edgar Filing: SOMANETICS CORP - Form 10-Q

result of a 39% increase in SomaSensor unit sales and a 13% increase in SomaSensor average selling prices, and an increase in Cerebral Oximeter revenues of approximately \$960,000, or 165%, due to increased purchases by pediatric hospitals. This increase was partially offset by a decrease in sales of the CorRestore System of approximately \$76,000, or 19%, and

- an increase in international sales of approximately \$993,000, or 71%, from approximately \$1,389,000 in the first three quarters of fiscal 2004 to approximately \$2,382,000 in the first three quarters of fiscal 2005, primarily attributable to increased purchases of the Cerebral Oximeter and SomaSensor by Tyco Healthcare.

As described above, during the first three quarters of 2005 we achieved a 13% increase in the average selling price of SomaSensors in the United States. The increase in the average selling price is primarily attributable to the addition of new customers at our higher suggested retail prices and increased sales of our pediatric SomaSensor, which sells for a premium price. In addition, as described above, we had a 39% increase in SomaSensor unit sales in the United States to 112,257 units. Internationally we sold 42,030 SomaSensors in the first nine months of 2005.

We placed 216 new Cerebral Oximeters in the United States, and 159 internationally, in the first three quarters of 2005.

Approximately 17% of our net revenues in the first three quarters of fiscal 2005 were from export sales, compared to approximately 16% of our net revenues in the first three quarters of fiscal 2004. One international distributor (Europe) accounted for approximately 12% of net revenues for the nine months ended August 31, 2005.

Sales of our products as a percentage of net revenues were as follows:

PRODUCT -----	PERCENT OF NET REVENUE FIRST THREE QUARTERS OF FISCAL	
	2005 ----	2004 ----
SomaSensors.....	77%	81%
Cerebral Oximeters...	20%	14%
CorRestore Systems...	3%	5%
Total.....	100%	100%
	===	===

### SOMANETICS CORPORATION

#### MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

AUGUST 31, 2005

Gross margin as a percentage of net revenues was approximately 87% for the nine months ended August 31, 2005 and approximately 83% for the nine months ended August 31, 2004. The increase in gross margin as a percentage of net

## Edgar Filing: SOMANETICS CORP - Form 10-Q

revenues is primarily attributable to the increase in the average selling price of SomaSensors described above, the reduction in the cost of our SomaSensor by approximately 40% in May 2004, and increased sales of the Cerebral Oximeter to pediatric hospitals in the United States.

Our research, development and engineering expenses increased \$27,023, or 10%, from \$269,418 for the nine months ended August 31, 2004 to \$296,441 for the nine months ended August 31, 2005. The increase is primarily attributable to development costs associated with the Cerebral Oximeter.

Selling, general and administrative expenses increased approximately \$2,875,000, or 49%, from \$5,810,669 for the nine months ended August 31, 2004 to \$8,685,648 for the nine months ended August 31, 2005, primarily due to a 62% increase in our sales and marketing expenses during the first three quarters of fiscal 2005 because of our increased sales personnel and our increased sales and marketing efforts. The increase in selling, general and administrative expense is primarily attributable to

- a \$682,000 increase in salaries, wages, and related expenses, primarily as a result of an increase in the number of employees, principally sales and marketing (from an average of 32 employees for the nine months ended August 31, 2004 to an average of 40 employees for the nine months ended August 31, 2005),
- a \$661,000 increase in commissions paid to our sales employees, as a result of hiring additional sales employees in fiscal 2004 and 2005 and increased sales,
- a \$519,000 increase in commissions paid to our independent sales representative firms as a result of increased sales,
- a \$423,000 increase in travel, training, trade show and selling-related expenses as a result of our increased sales personnel and increased sales and marketing efforts,
- a \$330,000 increase in accrued incentive compensation expense due to our year-to-date 2005 financial performance, primarily increased sales and net income, in accordance with the 2005 Incentive Compensation Plan,
- a \$255,000 increase in audit-related expenses, primarily as a result of costs associated with our first internal control assessment under Section 404 of the Sarbanes-Oxley Act, and
- \$118,000 in costs for the first nine months of fiscal 2005 associated with our employer 401(k) matching program, which was implemented in the fourth quarter of fiscal 2004.

During the first nine months of fiscal 2004 we incurred approximately \$96,000 of expenses as a result of the termination of some of our independent sales representative firms, and no such expenses were incurred during the first nine months of fiscal 2005.

During the first nine months of fiscal 2005, we recognized income tax expense at an estimated effective tax rate of 34% in our statement of operations.

## Edgar Filing: SOMANETICS CORP - Form 10-Q

### MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

AUGUST 31, 2005

For the nine-month period ended August 31, 2005, we realized net income of \$.21 per diluted share, compared to \$.11 per diluted share in fiscal 2004. This increased net income per diluted common share is primarily attributable to

- a 64% increase in net revenues,
- an increase in gross margin percentage to 87% from 83%, and
- a \$163,000 increase in interest income.

We achieved the increase in net income despite a 48% increase in operating expenses and the recognition of income tax expense.

#### LIQUIDITY AND CAPITAL RESOURCES

Net cash provided by operations during the nine-month period ended August 31, 2005 was approximately \$3,324,000. Cash was provided by

- net income of approximately \$2,448,000, non-cash income tax expense of approximately \$1,261,000, and depreciation and amortization expense of approximately \$277,000,
- an increase in accrued liabilities of approximately \$178,000, primarily due to increased accrued employee sales commissions as a result of higher sales, increased accrued incentive compensation as a result of our year-to-date fiscal 2005 financial performance, and increased accrued professional fees due to costs associated with our first internal control assessment under Section 404 of the Sarbanes-Oxley Act, partially offset by payments made in the first nine months for employer 401(k) matching contributions,
- an increase in accounts payable of approximately \$117,000, primarily because of increased inventories, increased sales commissions payable to our independent representative firms and partially offset by more timely payments to vendors, and
- a decrease in prepaid expenses of approximately \$104,000, primarily because of the amortization of prepaid insurance payments made in fiscal 2004.

Cash provided by operations was partially offset by

- an increase in inventories of approximately \$627,000 of SomaSensors and components associated with our Cerebral Oximeter, and
- an increase in accounts receivable of approximately \$442,000, primarily because of higher third quarter 2005 sales than fourth quarter 2004 sales, partially offset by faster collection of receivables in the third quarter of 2005.

The increase in inventories described above is greater than shown on our balance sheet because it includes Cerebral Oximeters that we capitalized because they are being used as demonstration units and no-cap sales equipment. We capitalized approximately \$390,000 of costs from inventory for Cerebral Oximeters being used as demonstration units and no-cap sales equipment at

## Edgar Filing: SOMANETICS CORP - Form 10-Q

customer locations during the first nine months of 2005, compared to approximately \$405,000 in the first nine months of fiscal 2004. We depreciate these assets over five years.

17

### SOMANETICS CORPORATION

#### MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

AUGUST 31, 2005

In addition, we had capital expenditures in the first nine months of fiscal 2005 of approximately \$120,000. These expenditures were primarily for computer equipment for our new employees, leasehold improvements to our facility, and furniture and fixtures associated with the leasehold improvements.

During the first three quarters of fiscal 2005, we issued 273,087 common shares as a result of stock option exercises, for proceeds of approximately \$1,425,000.

As of August 31, 2005, we had working capital of \$14,452,848, cash and cash equivalents of \$11,699,124, total current liabilities of \$1,528,081 and shareholders' equity of \$21,432,905. We had an accumulated deficit of \$42,433,891 through August 31, 2005.

For 2005, we expect to realize positive cash flow from operations, as well as a net increase in cash and cash equivalents, with year-end cash on hand expected to be approximately \$12.5 million.

#### CRITICAL ACCOUNTING POLICIES

We believe our most significant accounting policies relate to the recording of an intangible asset for license acquisition costs related to our acquisition of exclusive, worldwide, royalty-bearing licenses to specified rights relating to the CorRestore System and related products and accessories, our accounting treatment of stock options issued to employees, our accounting treatment for income taxes, and our revenue recognition associated with our no-cap sales program.

#### CORRESTORE INTANGIBLE ASSET

In fiscal years 2000, 2001 and 2003, we recorded an intangible asset related to our acquisition of exclusive, worldwide, royalty-bearing licenses to specified rights relating to the CorRestore System and related products and accessories. License acquisition costs included our estimate of the fair value of ten-year vested stock options to purchase common shares granted to one of our directors in connection with negotiating and assisting us in completing the transaction, and our estimate of the fair value of the vested portion of five-year warrants to purchase common shares issued in the transaction. Consistent with the treatment of the vested warrants to purchase common shares, we intend to include in license acquisition costs, and additional paid in capital, the fair value of the vested portion of the unvested warrants to purchase common shares, estimated using the Black-Scholes valuation model, when and if they become vested. However, we do not expect any of these remaining warrants to become vested before their November 21, 2006 expiration date, based on sales of CorRestore products to date.

We estimated the value of the stock options to purchase common shares and the vested warrants to purchase common shares using the Black-Scholes valuation

## Edgar Filing: SOMANETICS CORP - Form 10-Q

model. The Black-Scholes valuation model requires the following assumptions: expected life period of the security, expected volatility of our stock price during the period, risk-free interest rate, and dividend yield. Given the assumptions inherent in the Black-Scholes valuation model, it would have been possible to calculate a different value for our intangible asset by changing one or more of the valuation model variables or by using a different valuation model. However, we believe that the model is appropriate, that the judgments and assumptions that we made at the time of valuation were also appropriate, and that the reported results would not have been materially different had one or more of the variables been different or had a different valuation model been used.

18

### SOMANETICS CORPORATION

#### MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

AUGUST 31, 2005

We have adopted Statement of Financial Accounting Standards No. 142, "Goodwill and Other Intangible Assets." This statement establishes accounting and reporting standards for goodwill and other intangible assets. The effect of adopting this Statement has been to discontinue amortizing our license acquisition costs related to our acquisition of exclusive, worldwide, royalty-bearing licenses to specified rights relating to the CorRestore System and related products and accessories described above because we believe these licenses have an indefinite life. Therefore, we recorded no amortization expense related to these license acquisition costs in fiscal 2005 or 2004. It is possible to determine a different life for these licenses, and if they had a definite life, we would amortize the intangible asset over the remaining useful life. However, we believe it is appropriate to use an indefinite life for these licenses. Indefinite lived intangible assets are reviewed annually for impairment at the end of our fiscal year, and whenever events or changes in circumstances indicate that the carrying value of the asset may not be recovered. We evaluate impairment by comparing the fair value of the intangible asset, determined using a cash flow method, with its carrying value.

#### EMPLOYEE STOCK OPTIONS

In October 1995, Statement of Financial Accounting Standards No. 123, "Accounting for Stock-Based Compensation," was issued. In December 2004, the Financial Accounting Standards Board issued Statement of Financial Accounting Standards No. 123 (revised), Share Based Payment. This Statement revises Statement No. 123, "Accounting for Stock-Based Compensation," and requires that compensation costs related to share-based payment transactions, including stock options, stock appreciation rights and restricted stock be recognized in the financial statements. This Statement will be effective for our fiscal quarter ending February 28, 2006.

We currently account for stock-based compensation of employees using the intrinsic value method prescribed in Accounting Principles Board Opinion No. 25, "Accounting for Stock Issued to Employees," and related interpretations. Accordingly, compensation costs for stock options granted to employees are measured as the excess, if any, of the market price of our stock at the date of the grant over the amount an employee must pay to acquire the stock. No compensation expense has been charged against income for stock option grants to employees because our stock option grants are priced at the market value as of the date of grant. Stock-based compensation of consultants and advisors is determined based on the fair value of the options or warrants on the grant date

## Edgar Filing: SOMANETICS CORP - Form 10-Q

pursuant to the methodology of SFAS No. 123, estimated using the Black-Scholes model. The resulting amount is recognized as compensation expense and an increase in additional paid-in capital over the vesting period of the options or warrants. As a result, we recorded \$7,013 of compensation expense, and an equal increase in additional paid in capital, for stock options issued to non-employees during the first three quarters of fiscal 2005, and we recorded no such expense in fiscal 2004. During the first three quarters of fiscal 2005, we granted 168,257 stock options to our employees, directors and one of our consultants, and during the first three quarters of fiscal 2004, we granted 50,500 stock options to our employees and directors.

Had we recognized compensation expense for stock options that vested in the first three quarters of fiscal 2005 and 2004, using the fair value method of accounting based on the fair value of the options on the grant date using the Black-Scholes valuation model, our net income, on a pro forma basis, would have decreased by approximately \$1,309,000, or \$.11 per diluted common share, and \$567,000, or \$.05 per diluted common share, respectively.

19

### SOMANETICS CORPORATION

#### MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

AUGUST 31, 2005

#### INCOME TAXES

During fiscal 2004, we adjusted our deferred tax asset valuation allowance resulting in the recognition of a deferred tax asset of \$6,700,000 related to the expected future benefits of our net operating loss carryforwards, in accordance with Statement of Financial Accounting Standards No. 109, "Accounting for Income Taxes." We have performed the required assessment of positive and negative evidence regarding realization of our deferred tax assets in accordance with SFAS No. 109, including our past operating results, the existence of cumulative losses over our history up to the most recent two fiscal years, and our forecast for future net income. The primary assumption underlying our determination that the net asset will be realized is that our revenues and pre-tax income will grow in future years consistent with the original growth guidance given for fiscal 2005. Our assessment of our deferred tax assets, and the reversal of part of our valuation allowance, included evaluating our financial plans and our future projected earnings, making allowance for the uncertainties surrounding, among other things, our future rate of growth in net revenues, the rate of adoption of our products in the marketplace, and the potential for competition to enter the marketplace.

In reversing a portion of our valuation allowance, we have concluded that it is more likely than not that such assets will be realized. Given the assumptions inherent in our financial plans, it is possible to calculate a different value for our deferred tax asset by changing one or more of the variables in our assessment. However, we believe that our evaluation of our financial plans was reasonable, and that the judgments and assumptions that we made at the time of developing the plan were appropriate.

During the first quarter of fiscal 2005, we began recognizing income tax expense at an estimated effective tax rate of 34% on our statement of operations. As we assess our plans for future years, we will continue to review the appropriateness of adjusting our deferred tax asset valuation allowance and recognizing additional net deferred tax assets.

## Edgar Filing: SOMANETICS CORP - Form 10-Q

### NO-CAP SALES REVENUE RECOGNITION

We offer to our customers in the United States a no-cap sales program whereby we ship the Cerebral Oximeter to the customer at no charge, in exchange for the customer agreeing to purchase SomaSensors. We recognize SomaSensor revenue when we receive purchase orders and ship the product to the customer. Under our no-cap sales program, we do not recognize any revenue upon the initial shipment of the Cerebral Oximeter. At the time of shipment, we capitalize the Cerebral Oximeter as an asset and depreciate this asset over five years. We believe this is consistent with our stated revenue recognition policy, which is compliant with Staff Accounting Bulletin No. 104 and Emerging Issues Task Force No. 00-21, "Revenue Arrangements with Multiple Deliverables."

20

### SOMANETICS CORPORATION

### MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

AUGUST 31, 2005

### CONTRACTUAL OBLIGATIONS

As of August 31, 2005, there have been no material changes outside the ordinary course of business in the contractual obligations disclosed in our Annual Report on Form 10-K for the fiscal year ended November 30, 2004 under the caption "Contractual Obligations".

21

### ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Not applicable.

22

### ITEM 4. CONTROLS AND PROCEDURES

Our management has evaluated, with the participation of our principal executive and principal financial officers, the effectiveness of our disclosure controls and procedures as of August 31, 2005, and, based on their evaluation, our principal executive and principal financial officers have concluded that these controls and procedures are effective as of August 31, 2005. There was no change in our internal control over financial reporting identified in connection with such evaluation that occurred during our third fiscal quarter ended August 31, 2005 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

Disclosure controls and procedures are our controls and other procedures that are designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the Securities and Exchange Commission's rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is accumulated and communicated to our management, including our principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure.

PART II OTHER INFORMATION

ITEM 6. EXHIBITS

- 31.1 Certifications of Chief Executive Officer Pursuant to Rule 13a-14(a), as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
- 31.2 Certifications of Chief Financial Officer Pursuant to Rule 13a-14(a), as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
- 32.1 Certifications of Chief Executive Officer and Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Somanetics Corporation  
(Registrant)

Date: October 12, 2005

By: /s/ William M. Iacona

-----  
William M. Iacona  
Vice President, Finance, Controller, and  
Treasurer (Duly Authorized and  
Principal Financial Officer)

EXHIBIT INDEX

Exhibit -----	Description -----
31.1	Certifications of Chief Executive Officer Pursuant to Rule 13a-14(a), as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2	Certifications of Chief Financial Officer Pursuant to Rule 13a-14(a), as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1	Certifications of Chief Executive Officer and Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.



